论文部分内容阅读
目的观察周剂量紫杉醇(PTX)同步放化疗治疗中晚期食管癌的疗效及毒副反应。方法55例失去手术机会的ⅢBⅣ-期食管癌患者分为两组,治疗组33例采用同步放化疗,放疗同时配合紫杉醇周剂量给药,对照组22例单纯放疗。结果治疗组有效率90.9%,对照组有效率59.1%(χ2=6.08,P<0.05);治疗组1,2年生存率高于对照组(χ2=4.38,P<0.05),两组对比差异有统计学意义。主要毒性为胃肠道反应,食管炎及骨髓抑制,程度多为Ⅰ°~Ⅲ°,大多可以耐受。结论周剂量紫杉醇同步放化疗治疗中晚期食管癌较单纯放疗疗效好,毒性可耐受。
Objective To observe the efficacy and toxicities of weekly paclitaxel (PTX) concurrent chemoradiotherapy in the treatment of advanced esophageal cancer. Methods Fifty-five patients with stage ⅢBⅣ-stage esophageal cancer who had lost operation were divided into two groups. 33 cases in the treatment group received concurrent chemoradiotherapy and radiotherapy combined with the weekly paclitaxel administration, and 22 cases in the control group received radiotherapy alone. Results The effective rate was 90.9% in the treatment group and 59.1% in the control group (χ2 = 6.08, P <0.05). The 1-year and 2-year survival rates were significantly higher in the treatment group than those in the control group (χ2 = 4.38, There is statistical significance. The main toxicity of gastrointestinal reactions, esophagitis and bone marrow suppression, mostly degree Ⅰ ° ~ Ⅲ °, most can be tolerated. Conclusions Weekly paclitaxel concurrent chemoradiotherapy is superior to radiotherapy in the treatment of advanced esophageal cancer, and its toxicity is tolerable.